However, a study with 404 patients of NSCLC found that a higher RIPK3 expression is associated with shorter overall survival and a tendency of shorter DFS, which might be caused by the resistance to radiotherapy or excessive necroptosis-mediated damage (Kim et al., 2020). Here, RIPK3 is linked to non-small cell lung carcinoma.